Drug shortage
Bupivacaine Hydrochloride Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Bupivacaine Hydrochloride Injection |
|---|---|
| Proprietary name | Bupivacaine Hydrochloride |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01) |
| Dosage form | Injection |
| Strength | 125 mg/50 mL (2.5 mg/mL) |
| Status | Current |
| Therapeutic category | Anesthesia |
| Package NDCs | 0409-1160-01 |
| First posted | Feb 20, 2018 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: